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Melanoma is currently the most lethal form of skin cancer.
Clinical efforts to combat melanoma have included
approaches to induce the immune system, through T-cell
directed therapies, to clear melanoma. These approaches
require that immune cells enter the tumor microenviron-
ment to be clinically beneficial. However, most tumors
lack significant immune infiltration prior to immune ther-
apy, and immune therapies are hindered by a persistent
lack of immune cell infiltration. Chemokines can promote
T-cell migration into tumors; therefore agents that induce
chemokine production by melanoma cells to promote
T-cell infiltration may be clinically beneficial, and could
potentially work synergistically with current immune
treatments for melanoma. We hypothesized that TLR liga-
tion of melanoma would induce immune cell attracting
chemokine secretion directly from melanoma cells, alone
or in combination with IFNg. To test this hypothesis, we
treated human melanoma cell lines (VMM1, DM13,
DM93 and DM122) individually with TLR agonists and
analyzed effects on the expression of chemokines CCL2-5,
CXCL9-10, and CXCL12 by flow cytometric analysis. The
following TLR agonists were tested: MALP-2 and FSL-1
(TLR2/6), poly-ICLC (TLR3), LPS (TLR4), CpG (TLR9),
Resiquimod (TLR7/8), Imiquimod (TLR7). Our studies
found that melanoma express TLRs 2, 3, 4, 6, 7, and 9, but
that without exogenous stimulation, melanoma cells pro-
duce few immune cell attracting chemokines. Further-
more, stimulation of melanoma with the TLR agonists
alone induced little chemokine production. However,
TLR2/6 treatment of melanoma cells (MALP-2 or FSL-1)
given in combination with IFNg resulted in significant
increases in CXCL10 and CCL3 chemokine production by
melanoma. We found that TLR2 and TLR6 are widely
expressed on human melanoma cells. Furthermore, stimu-
lation of fresh patient melanoma specimens with TLR2/6
agonists plus IFNg induces CXCL10 production from mel-
anoma cells, endothelial cells and, to a lesser extent, sev-
eral immune cell subsets including dendritic, monocytic,
macrophage, and B-cell. Finally, ex vivo migration assays
demonstrated that stimulation of melanoma cells with
TLR2/6 agonists plus IFNg increases CD4+ and CD8+
T-cell migration toward melanoma cells. CXCL10 has
been implicated as a critical chemokine supporting T-cell
infiltration into the tumor microenvironment. Collectively,
these data identify TLR2/6 agonists and IFNg as key indu-
cers of CXCL10 production by melanoma cells and sug-
gest that for tumors lacking immune cell infiltrates,
systemic immune therapies may be improved by combina-
tion with intralesional therapy using TLR2/6 agonists plus
IFNg.
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